Clinical trials: Pneumococcal Vaccine
Healthy
Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay
The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.
- Trial name
- NCT00508950
- Testing
- Large volume blood draw
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Pfizer
Immunization Programs
Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through GP Clinics
Pneumonia and influenza are among the top causes of hospitalisation and death in the elderly. While vaccinations are recommended against these diseases, a large proportion of elderly in the community remain unvaccinated, with…
- Trial name
- NCT03445117
- Testing
- Educational intervention
- Where
- 2 sites in Singapore
- Volunteers
- 8,837 people
- Sponsor
- Tan Tock Seng Hospital
HIV, Pneumonia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus.
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Trial name
- NCT05794191
- Testing
- Vaccine Administration
- Where
- United States
- Volunteers
- 350,399 people
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers. This study is enrolling participants who are: Born after at least 36 weeks of pregnancy and about 2 months of…
- Trial name
- NCT05512819
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 11 sites in India, Taiwan
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Pfizer
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
Assess immuno, reacto of the 10-valent pneumococcal vaccine after 2 doses (2, 4 months of age) and after the complete 2, 4, 11 months schedule when co-administered with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (according to national…
- Trial name
- NCT00307034
- Testing
- GSK Biologicals' 10-valent pneumococcal conjugate vaccine., Infanrix hexa., Infanrix-IPV/Hib.
- Where
- 8 sites in Denmark, Norway and 2 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccination
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70 years old in Shanghai.
- Trial name
- NCT04700618
- Testing
- 23-valent pneumococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Asthma
Pneumococcal Vaccines in Patients With Asthma
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
- Trial name
- NCT03260790
- Testing
- PCV13, PPSV23
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
- Trial name
- NCT03512288
- Testing
- Multivalent, 13vPnC
- Where
- 39 sites in United States
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
- Trial name
- NCT04357522
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine, 13-Valent Pneumococcal Conjugate Vaccine
- Where
- 3 sites in China
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
HIV Infections, Pneumococcal Infections
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects.
- Trial name
- NCT00000829
- Testing
- Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Meningitis
Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea
The National Health Plan 2001-2010 calls for investigation of the feasibility of pneumococcal vaccines for Papau New Guinea. The Papua New Guinea (PNG) Institute of Medical Research, the Telethon Institute for Child Health…
- Conditions
- Pneumonia, Meningitis, Otitis Media
- Trial name
- NCT00219401
- Testing
- Pneumococcal 7 valent conjugate vaccine (Prevenar®)
- Where
- Papua New Guinea
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Immune Tolerance
Pneumococcal Conjugate Vaccine Followup
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to potential immunological hypo-responsiveness (i.e. a poorer immune response to repeat vaccination).
- Trial name
- PCVFU (NCT01414504)
- Testing
- Prevenar + PPV, Infant PCV (Prevenar) + PPV at 9 months, No Prevenar + PPV at 9 months
- Where
- Papua New Guinea
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- William Pomat
Rheumatoid Arthritis
Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients
Is pneumococcal conjugate vaccine (which induces a T-dependent humoral response) more efficient than pneumococcal polysaccharide vaccine (which induces a T-independent humoral response) in RA patients treated with abatacept…
- Trial name
- VACINA (NCT02547493)
- Testing
- pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, Abatacept
- Where
- 11 sites in France, Monaco
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Acute Otitis Media
Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children
This clinical study is designed to assess prospectively the sero-responses to various proteins in cases of pneumococcal Acute Otitis Media.
- Trial name
- NCT01214538
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- NasVax Ltd
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
This study is designed to evaluate the safety, tolerability, and immunogenicity of two different lots of V114 in healthy infants 6 to 12 weeks (>=42 days to <=90 days) of age.
- Trial name
- NCT02987972
- Testing
- V114 Lot 1, V114 Lot 2, Prevnar 13™
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Streptococcus Pneumoniae
Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status
Community acquired pneumonia (CAP) is an important health problem with significant morbidity, mortality and cost. The most identified pathogen in CAP is Streptococcus pneumoniae.
- Conditions
- Pneumonia, Streptococcus Pneumoniae, Immune Response
- Trial name
- CAPolista (NCT02141009)
- Testing
- Prevnar 13
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- St. Antonius Hospital
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group…
- Trial name
- NCT06531538
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Pfizer
Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell…
- Conditions
- Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
- Trial name
- NCT02309515
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic